المؤلفون: Lengliné E; Hematology department, Hôpital Saint-Louis AP-HP, Paris, France. Electronic address: etienne.lengline@aphp.fr., Baba J; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., de Boissieu P; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., Beaufils A; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., Desbiolles A; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., Diatta T; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., Cochat P; Drug evaluation department, Haute Autorité de Santé, Saint Denis Paris France., Chevret S; ECSTRRA Team, Université Paris Cité, UMR1153, INSERM, Paris, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jun; Vol. 204, pp. 114047. Date of Electronic Publication: 2024 Apr 12.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Progression-Free Survival* , Neoplasms*/drug therapy , Neoplasms*/mortality , Technology Assessment, Biomedical*, Humans ; Endpoint Determination ; France ; Research Design/standards

المؤلفون: Buyukbayram ME; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey. m.eminbuyukbayram@hotmail.com., Hannarici Z; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Turhan A; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Caglar AA; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Esdur PÇ; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Bilici M; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Tekin SB; Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey., Erdemci B; Department of Radiation Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey.

المصدر: BMC cancer [BMC Cancer] 2024 May 23; Vol. 24 (1), pp. 626. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Uterine Cervical Neoplasms*/mortality , Uterine Cervical Neoplasms*/blood , Uterine Cervical Neoplasms*/pathology , C-Reactive Protein*/metabolism , C-Reactive Protein*/analysis , Biomarkers, Tumor*/blood , Progression-Free Survival*, Humans ; Female ; Middle Aged ; Prognosis ; Retrospective Studies ; Adult ; Blood Glucose/analysis ; Blood Glucose/metabolism ; Aged ; Kaplan-Meier Estimate ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/blood ; ROC Curve ; Adenocarcinoma/mortality ; Adenocarcinoma/blood ; Adenocarcinoma/pathology

المؤلفون: Durie BGM; Cedars-Sinai Outpatient Cancer Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. bdurie@myeloma.org., Kumar SK; Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA., Ammann EM; Janssen Global Market Access, Raritan, NJ, USA., Fu AZ; Janssen Scientific Affairs, Horsham, PA, USA.; Georgetown University Medical Center, Washington, DC, USA., Kaila S; Janssen Scientific Affairs, Horsham, PA, USA., Lam A; Janssen Global Market Access, Raritan, NJ, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Facon T; University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France.

المصدر: Advances in therapy [Adv Ther] 2024 May; Vol. 41 (5), pp. 1923-1937. Date of Electronic Publication: 2024 Mar 18.

نوع المنشور: Journal Article; Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Lenalidomide*/therapeutic use , Dexamethasone*/therapeutic use , Dexamethasone*/administration & dosage , Bortezomib*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Progression-Free Survival*, Humans ; Aged ; Female ; Male ; Middle Aged ; Antibodies, Monoclonal/therapeutic use ; Aged, 80 and over

المؤلفون: Davison MA; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Lilly DT; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Patel AA; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Kashkoush A; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Chen X; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Wei W; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Benzel EC; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Prayson RA; Department of Anatomic Pathology, The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA., Chao S; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Angelov L; Department of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. angelol@ccf.org.; Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA. angelol@ccf.org.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. angelol@ccf.org.; Neurologic Oncology and Radiosurgery Fellowships, Neurological Surgery, CCLCM at CWRU, Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, 9500 Euclid Ave., CA-51, 44195, Cleveland, OH, USA. angelol@ccf.org.

المصدر: Journal of neuro-oncology [J Neurooncol] 2024 May; Vol. 167 (3), pp. 437-446. Date of Electronic Publication: 2024 Mar 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE

مواضيع طبية MeSH: Ependymoma*/surgery , Ependymoma*/mortality , Ependymoma*/pathology , Spinal Cord Neoplasms*/surgery , Spinal Cord Neoplasms*/mortality , Spinal Cord Neoplasms*/pathology , Neurosurgical Procedures*/mortality , Progression-Free Survival*, Humans ; Male ; Female ; Middle Aged ; Adult ; Follow-Up Studies ; Retrospective Studies ; Survival Rate ; Young Adult ; Aged ; Prognosis ; Adolescent

المؤلفون: Dimopoulos M; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Sonneveld P; Erasmus Medical Center, Rotterdam, the Netherlands., Manier S; University of Lille, Lille, France., Lam A; Janssen Global Services, Raritan, NJ, USA., Roccia T; Janssen Global Services, Raritan, NJ, USA., Schecter JM; Janssen Research & Development, Raritan, NJ, USA., Cost P; Janssen Global Services, Raritan, NJ, USA., Pacaud L; Legend Biotech USA Inc, Somerset, NJ, USA., Poirier A; Cytel Inc. Health Economics & Outcomes Research, Waltham, MA, USA., Tremblay G; Cytel Inc. Health Economics & Outcomes Research, Waltham, MA, USA., Lan T; Cytel Inc. Health Economics & Outcomes Research, Waltham, MA, USA., Valluri S; Janssen Global Services, Raritan, NJ, USA., Kumar S; Department of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.

المصدر: BMC cancer [BMC Cancer] 2024 Apr 29; Vol. 24 (1), pp. 541. Date of Electronic Publication: 2024 Apr 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/pathology , Progression-Free Survival* , Randomized Controlled Trials as Topic*, Humans ; Neoplasm Recurrence, Local/mortality ; Female ; Male

المؤلفون: Herzog M; Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia., Verdenik I; Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia., Kobal B; Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia.; Department of Gynecology and Obstetrics, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia., Černe K; Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 20; Vol. 25 (12). Date of Electronic Publication: 2024 Jun 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Epithelial Cell Adhesion Molecule*/metabolism , Extracellular Vesicles*/metabolism , Ascites*/metabolism , Ascites*/pathology , Biomarkers, Tumor*/metabolism , Progression-Free Survival* , Cystadenocarcinoma, Serous*/metabolism , Cystadenocarcinoma, Serous*/pathology , Cystadenocarcinoma, Serous*/mortality , Ovarian Neoplasms*/metabolism , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/mortality, Humans ; Female ; Middle Aged ; Aged ; Prognosis ; Adult ; Neoplasm Grading

المؤلفون: Kınıkoğlu O; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Odabas H; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Altıntaş YE; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldız A; Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul 34093, Turkey., Çakan B; Department of Medical Oncology, Bağcılar Research and Training Hospital, Istanbul 34212, Turkey., Akdağ G; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldırım S; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Bal H; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Kaya T; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Tünbekici S; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir 35100, Turkey., Işık D; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Başoğlu T; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldırım ME; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Turan N; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.

المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jun 07; Vol. 60 (6). Date of Electronic Publication: 2024 Jun 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/mortality , Receptor, ErbB-2*/analysis , Ado-Trastuzumab Emtansine*/therapeutic use , Progression-Free Survival*, Humans ; Female ; Middle Aged ; Aged ; Adult ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Neoplasm Metastasis ; Aged, 80 and over ; Trastuzumab/therapeutic use ; Receptors, Estrogen/analysis ; Receptors, Estrogen/metabolism

المؤلفون: Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. matthias.preusser@meduniwien.ac.at., Kazda T; Department of Radiation Oncology and Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic., Le Rhun E; Department of Medical Oncology and Hematology, University Hospital & University of Zurich, Zurich, Switzerland., Sahm F; Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, DKFZ, Heidelberg, Germany., Smits M; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands., Gempt J; Department of Neurosurgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Koekkoek JA; Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands., Monti AF; Department of Medical Physics, ASST GOM Niguarda, Milano, Italy., Csanadi M; Syreon Research Institute, Budapest, Hungary., Pitter JG; Syreon Research Institute, Budapest, Hungary., Bulbek H; Brainstrust-the brain cancer people, Isle of Wight, Cowes, UK., Fournier B; EORTC Headquarters Team, Brussels, Belgium., Quoilin C; EORTC Headquarters Team, Brussels, Belgium., Gorlia T; EORTC Headquarters Team, Brussels, Belgium., Weller M; Department of Neurology, University Hospital & University of Zurich, Zurich, Switzerland., Minniti G; Department of Radiological Sciences, Oncology and Anatomical Pathology and IRCCS Neuromed (IS), Sapienza University, Policlinico Umberto I, Rome, Italy.

مؤلفون مشاركون: European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group

المصدر: Trials [Trials] 2024 Jun 07; Vol. 25 (1), pp. 366. Date of Electronic Publication: 2024 Jun 07.

نوع المنشور: Journal Article; Clinical Trial Protocol

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

مواضيع طبية MeSH: Glioblastoma*/pathology , Glioblastoma*/drug therapy , Glioblastoma*/mortality , Glioblastoma*/radiotherapy , Glioblastoma*/therapy , Lomustine*/administration & dosage , Lomustine*/therapeutic use , Lomustine*/adverse effects , Brain Neoplasms*/radiotherapy , Brain Neoplasms*/pathology , Brain Neoplasms*/mortality , Brain Neoplasms*/therapy , Disease Progression* , Antineoplastic Agents, Alkylating*/therapeutic use , Multicenter Studies as Topic* , Progression-Free Survival*, Humans ; Quality of Life ; Randomized Controlled Trials as Topic ; Chemoradiotherapy/methods ; Clinical Trials, Phase III as Topic ; Pragmatic Clinical Trials as Topic ; Time Factors

المؤلفون: Gafita A; Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; agafita1@jhmi.edu.; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California., Djaileb L; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.; LRB, Nuclear Medicine Department, CHU Grenoble Alpes, INSERM, Université Grenoble Alpes, Grenoble, France., Rauscher I; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany., Fendler WP; Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Hadaschik B; Department of Urology, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Rowe SP; Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina., Herrmann K; Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Solnes LB; Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California., Rettig MB; Department of Urology, David Geffen School of Medicine, UCLA, Los Angeles, California.; VA Greater Los Angeles, Los Angeles, California., Weber M; Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Farolfi A; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.; Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and., Benz MR; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.; Department of Radiological Sciences, UCLA, Los Angeles, California., Eiber M; Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Jun 03; Vol. 65 (6), pp. 917-922. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Prostatic Neoplasms, Castration-Resistant*/pathology , Radiopharmaceuticals*/therapeutic use , Lutetium*/therapeutic use , Neoplasm Metastasis* , Progression-Free Survival* , Positron Emission Tomography Computed Tomography*, Humans ; Male ; Aged ; Retrospective Studies ; Middle Aged ; Aged, 80 and over ; Glutamate Carboxypeptidase II/metabolism ; Prostate-Specific Antigen/blood ; Antigens, Surface/metabolism ; Treatment Outcome ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Radioisotopes

المؤلفون: Taliento C; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium., Morciano G; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy., Nero C; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Università Cattolica del Sacro Cuore Dipartimento Scienze della Vita e Sanità Pubblica, Rome, Italy., Froyman W; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.; Department of Obstetrics and Gynecology, University Hospitals KU Leuven, Leuven, Belgium., Vizzielli G; Department of Obstetrics and Gynecology, University of Udine Medical Area Department, Udine, Italy., Pavone M; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; IHU Strasbourg, Institute of Image Guided Surgery, Strasbourg, France., Salvioli S; Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy., Tormen M; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Fiorica F; Azienda ULSS 9 Scaligera, Verona, Veneto, Italy., Scutiero G; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Scambia G; Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Giorgi C; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy., Greco P; Department of Medical Sciences, Obstetrics and Gynecology Unit, 'S. Anna' University Hospital, University of Ferrara, Ferrara, Italy., Pinton P; Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy paolo.pinton@unife.it.

المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Jun 03; Vol. 34 (6), pp. 906-918. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Systematic Review; Meta-Analysis

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Ovarian Epithelial*/mortality , Carcinoma, Ovarian Epithelial*/blood , Carcinoma, Ovarian Epithelial*/genetics , Carcinoma, Ovarian Epithelial*/pathology , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Ovarian Neoplasms*/blood , Ovarian Neoplasms*/mortality , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Progression-Free Survival* , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/genetics, Humans ; Female